TREAT NOW, PROVE LATER? EU5 PAYER PERSPECTIVES ON PRE-SYMPTOMATIC GENE THERAPY FOR HUNTINGTON'S DISEASE
Author(s)
Rachael McRobb, BSc, MSc, Rebecca Andrews, MChem, Richard Macaulay, BA, PhD.
Precision AQ, London, United Kingdom.
Precision AQ, London, United Kingdom.
Presentation Documents
OBJECTIVES: Huntington's disease (HD) is a fatal neurodegenerative condition caused by a single gene mutation. Carriers can be genetically identified decades before symptoms appear, typically in their 20s-30s, with symptom onset usually in the 40s-50s. Emerging gene therapy has shown evidence of delaying disease progression in early-symptomatic patients; however, prescriber and patient demand to treat earlier is expected to be strong, despite clinical benefit only becoming observable 10-20+ years later. This research assesses EU5 payer willingness to reimburse a one-time gene therapy for genetically confirmed but pre-symptomatic HD patients and characterises required evidence and acceptable risk-sharing arrangements.
METHODS: A structured survey was conducted with N=15 ex-payer experts across EU5 markets (N=3 per market). Respondents indicated reimbursement willingness, required evidence (surrogate biomarkers, extrapolation from early symptomatic trial data, long-term registries), appropriateness of existing HTA frameworks (including discount rates) for preventative gene therapies, and preferred risk-sharing structures.
RESULTS: Reimbursement appetite split between 'yes in principle' (60%), 'possibly with conditions' (20%), and 'unlikely/no' (20%). Of those expecting reimbursement possible, 41% accepted surrogate biomarkers, 31% preferred extrapolation from early symptomatic data, 26% could not recommend evidence given disease complexity, and 31% required long-term registries to confirm durability. Most (67%) deemed current HTA frameworks inadequate for preventative gene therapies, calling for natural-history modelling and periodic re-evaluation. Discount rates were judged appropriate by 80%; 20% favoured lower rates for preventative therapies. Preferred contracting was outcomes-based with long follow-up (33%) and coverage-with-evidence-development (33%).
CONCLUSIONS: EU5 payers acknowledge HD gene therapy's transformative potential but require robust natural-history evidence, long-term registries, and outcomes-based contracting to bridge the pre-symptomatic evidence gap. Manufacturers should anticipate conditional reimbursement, with limited payer appetite for discount-rate adjustment despite the long horizon.
METHODS: A structured survey was conducted with N=15 ex-payer experts across EU5 markets (N=3 per market). Respondents indicated reimbursement willingness, required evidence (surrogate biomarkers, extrapolation from early symptomatic trial data, long-term registries), appropriateness of existing HTA frameworks (including discount rates) for preventative gene therapies, and preferred risk-sharing structures.
RESULTS: Reimbursement appetite split between 'yes in principle' (60%), 'possibly with conditions' (20%), and 'unlikely/no' (20%). Of those expecting reimbursement possible, 41% accepted surrogate biomarkers, 31% preferred extrapolation from early symptomatic data, 26% could not recommend evidence given disease complexity, and 31% required long-term registries to confirm durability. Most (67%) deemed current HTA frameworks inadequate for preventative gene therapies, calling for natural-history modelling and periodic re-evaluation. Discount rates were judged appropriate by 80%; 20% favoured lower rates for preventative therapies. Preferred contracting was outcomes-based with long follow-up (33%) and coverage-with-evidence-development (33%).
CONCLUSIONS: EU5 payers acknowledge HD gene therapy's transformative potential but require robust natural-history evidence, long-term registries, and outcomes-based contracting to bridge the pre-symptomatic evidence gap. Manufacturers should anticipate conditional reimbursement, with limited payer appetite for discount-rate adjustment despite the long horizon.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA172
Topic
Health Technology Assessment, Medical Technologies
Topic Subcategory
Decision & Deliberative Processes
Disease
Neurological Disorders